Cover Image
Market Research Report
Product code 
927151

Metachromatic Leukodystrophy (MLD) - Competitive Landscape, Market and Pipeline Analysis, 2020

Published: Pre-Order | DelveInsight Business Research LLP | Delivery time: 2-10 business days

Price

Back to Top
Metachromatic Leukodystrophy (MLD) - Competitive Landscape, Market and Pipeline Analysis, 2020
Published: Pre-Order
DelveInsight Business Research LLP
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

Overview

According to National Institute of Health (NIH), Metachromatic Leukodystrophy (MLD) is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. This accumulation especially affects cells in the nervous system that produce myelin, the substance that insulates and protects nerves. Nerve cells covered by myelin make up a tissue called white matter.

"Metachromatic Leukodystrophy (MLD) - Competitive Landscape, Market and Pipeline Analysis, 2020" report provides comprehensive insights on the therapeutic development for this mechanism of action. The objective of the report is to establish an understanding of the therapeutic competitive landscape for Metachromatic Leukodystrophy (MLD), including the pipeline products in this space. It further offers comparative pipeline analysis with their drug profiles at various stages of development covering Phase III, Phase II, Phase I, Preclinical and Discovery. Information on company collaborations, agreements, acquisitions, licensing, deals, and other development activities is also involved in this report Therapeutics assessment of active pipeline drugs by stage, therapy type, route of administration, and molecule type is also covered in this report. It features the inactive pipeline products and highlights currently undergoing institutional research in this area. The report provides the understanding of the unmet needs, market drivers and barriers of the Metachromatic Leukodystrophy market.

Future competitive landscape of Metachromatic Leukodystrophy (MLD) is estimated to be very strong. Key emerging drugs including Takeda's TAK-611 and others are going to be Blockbuster in the upcoming years.

Delveinsight report on Metachromatic Leukodystrophy (MLD) help companies in understanding market dynamics based on this mechanism of action and therefore giving opportunities for a strategic alliance that will result in market penetration and enhancement of portfolios with optimal investment and maximal return. In addition, reports will assuage companies to detect conditions, determine genetic predisposition and biological response to Metachromatic Leukodystrophy (MLD).

Metachromatic Leukodystrophy (MLD) Report Key Features

The report provides insights into:

  • A number of companies developing therapies of Metachromatic Leukodystrophy (MLD) with aggregate therapies developed by each company for the same.
  • Detailed profiles of therapeutic candidates in nonclinical stage, early-stage, mid-stage and late-stage of development for Metachromatic Leukodystrophy (MLD).
  • Analyses key players involved in Metachromatic Leukodystrophy (MLD) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Active pipeline therapies assessment under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detail analysis of collaboration (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future developments of Metachromatic Leukodystrophy (MLD).

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Metachromatic Leukodystrophy (MLD) Analytical Perspective by DelveInsight

  • In-depth Metachromatic Leukodystrophy (MLD) Analysis: Assessment of Products

This report provides an in-depth commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, agreements, licensing, and acquisition - deal value trends. The sub-segmentation is described in the report which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

  • Metachromatic Leukodystrophy (MLD) Clinical Assessment of Products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this mechanism of action.

Scope of the Report

  • The Metachromatic Leukodystrophy report provides an overview of this mechanism of action, role, significance, pathway, types, and clinical application of IDH inhibitors.
  • Therapeutic Assessment: Therapeutic pipeline activity and assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of therapeutic products for Metachromatic Leukodystrophy (MLD) with key coverage of developmental activities, including collaborations, agreements, licensing, mergers and acquisition, funding, designations, technology and other product-related details.
  • In-depth Metachromatic Leukodystrophy research and development progress and trial details results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Metachromatic Leukodystrophy (MLD).
  • Key topics covered include strategic competitor assessment, market characterization, opportunities, unmet needs, market growth factors, barriers and challenges along with SWOT analysis of the Metachromatic Leukodystrophy market.
  • Analysis of the current and future market competition in the global Metachromatic Leukodystrophy market. Current scenario of the market with upcoming blockbuster molecules and their impact on the overall market.

Report Highlights

  • In the coming years, the Metachromatic Leukodystrophy market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metachromatic Leukodystrophy R&D. The Metachromatic Leukodystrophy therapies under development are focused on novel approaches to treat/improve the disease condition.
  • There are many companies involved in developing therapies for Metachromatic Leukodystrophy (MLD). Launch of emerging therapies of Metachromatic Leukodystrophy (MLD) will significantly impact the market.
  • A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Metachromatic Leukodystrophy (MLD).
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late-stage of development for the treatment of Metachromatic Leukodystrophy (MLD) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
  • The report provides the detailed analysis of 8+ products along with 7+ companies involved.

Companies Mentioned

  • Orchard Therapeutics
  • Takeda
  • Magenta Therapeutics

And many more …

Key Questions

  • What are Metachromatic Leukodystrophy (MLD), their role and significance in the treatment of disease conditions?
  • What are the current treatment options based on the Metachromatic Leukodystrophy (MLD) available in the market?
  • How many therapies are developed by each company for Metachromatic Leukodystrophy (MLD) to treat disease conditions?
  • What are the key collaborations (Industry-Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the Metachromatic Leukodystrophy therapies?
  • Which are the dormant and discontinued products and the reasons for dormancy and discontinuation?
  • What is the unmet need for current therapies developed on the basis of this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metachromatic Leukodystrophy (MLD) and their status?
Table of Contents
Product Code: DICL0005

Table of Contents

1. Report Introduction

2. Metachromatic Leukodystrophy (MLD)

  • 2.1. Metachromatic Leukodystrophy (MLD) Overview
  • 2.2. Metachromatic Leukodystrophy (MLD) Types
  • 2.3. Metachromatic Leukodystrophy (MLD) Structure
  • 2.4. Metachromatic Leukodystrophy (MLD) Mechanism of Action
  • 2.5. Metachromatic Leukodystrophy (MLD) Application

3. Competitive Landscape

4. Metachromatic Leukodystrophy (MLD) - DelveInsight's Analytical Perspective

  • 4.1. In-depth Commercial Assessment
    • 4.1.1. Metachromatic Leukodystrophy (MLD) Companies Collaborations, Licensing, Acquisition - Deal Value Trends
      • 4.1.1.1. Assessment Summary
    • 4.1.2. Metachromatic Leukodystrophy (MLD) Collaboration Deals
      • 4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
      • 4.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
      • 4.1.2.3. Metachromatic Leukodystrophy (MLD) Acquisition Analysis

5. Therapeutic Assessment

  • 5.1. Clinical Assessment of Pipeline Drugs
    • 5.1.1. Assessment by Stage of Development
    • 5.1.2. Assessment by Product Type (Mono/Combination)
      • 5.1.2.1. Assessment by Stage and Product Type
    • 5.1.3. Assessment by Route of Administration
      • 5.1.3.1. Assessment by Stage and Route of Administration
    • 5.1.4. Assessment by Molecule Type
      • 5.1.4.1. Assessment by Stage and Molecule Type
    • 5.1.5. Assessment by MOA
      • 5.1.5.1. Assessment by Stage and MOA
    • 5.1.6. Assessment by Target
      • 5.1.6.1. Assessment by Stage and Target

6. Pipeline Therapeutics

  • 6.1. Comparative Analysis

7. Late-Stage Products (Phase-III)

8. Mid-Stage Products (Phase-II)

9. Early-Stage Products (Phase-I)

10. Preclinical and Discovery Stage Products

11. Metachromatic Leukodystrophy (MLD) Emerging Drug Profiles

  • 11.1. TAK-611: Takeda
    • 11.1.1. Product Description
    • 11.1.2. Research and Development
      • 11.1.2.1. Clinical Studies
    • 11.1.3. Product Development Activities
    • 11.1.4. Tabulated Product Summary
      • 11.1.4.1. General Description Table

Many more drugs with detailed profiles provided in the report …

12. Metachromatic Leukodystrophy (MLD) Key Companies

13. Metachromatic Leukodystrophy (MLD) Key Products

14. Inactive Products

  • 14.1. Dormant Products
    • 14.1.1. Reason for Dormancy
  • 14.2. Discontinued Products
    • 14.2.1. Reason for Discontinuation

15. Metachromatic Leukodystrophy (MLD) - Unmet Needs

16. Metachromatic Leukodystrophy (MLD) - Market Drivers and Barriers

17. Metachromatic Leukodystrophy (MLD) - Future Perspectives and Conclusion

18. Metachromatic Leukodystrophy (MLD) Analyst Views

19. Appendix

20. Report Methodology

  • 20.1. Secondary Research
  • 20.2. Expert Panel Validation

List of Tables

  • Table 1 Assessment Summary
  • Table 2 Company-Company Collaborations (Licensing/Partnering) Analysis
  • Table 3 Metachromatic Leukodystrophy (MLD) Acquisition Analysis
  • Table 4 Assessment by Phase of Development
  • Table 5 Assessment by Product Type (Mono/Combination)
  • Table 6 Assessment by Stage and Product Type
  • Table 7 Assessment by Route of Administration
  • Table 8 Assessment by Stage and Route of Administration
  • Table 9 Assessment by Molecule Type
  • Table 10 Assessment by Stage and Molecule Type
  • Table 11 Assessment by MOA
  • Table 12 Assessment by Stage and MOA
  • Table 13 Assessment by Target
  • Table 14 Assessment by Stage and Target
  • Table 15 Late-Stage Products (Phase-III)
  • Table 16 Mid-Stage Products (Phase-II)
  • Table 17 Early-Stage Products (Phase-I)
  • Table 18 Preclinical and Discovery Stage Products
  • Table 19 Inactive Products
  • Table 20 Dormant Products
  • Table 21 Discontinued Products

List of Figures

  • Figure 1 Metachromatic Leukodystrophy (MLD) Structure
  • Figure 2 Metachromatic Leukodystrophy (MLD) Mechanism
  • Figure 3 Metachromatic Leukodystrophy (MLD) Types
  • Figure 4 Metachromatic Leukodystrophy (MLD) Clinical Significance
  • Figure 5 Metachromatic Leukodystrophy (MLD) companies collaborations, Licensing, Acquisition - Deal Value Trends
  • Figure 6 Company-Company Collaborations (Licensing/Partnering) Analysis
  • Figure 7 Metachromatic Leukodystrophy (MLD) Acquisition Analysis
  • Figure 8 Assessment by Phase of Development
  • Figure 9 Assessment by Product Type (Mono/Combination)
  • Figure 10 Assessment by Stage and Product Type
  • Figure 11 Assessment by Route of Administration
  • Figure 12 Assessment by Stage and Route of Administration
  • Figure 13 Assessment by Molecule Type
  • Figure 14 Assessment by Stage and Molecule Type
  • Figure 15 Assessment by MOA
  • Figure 16 Assessment by Stage and MOA
  • Figure 17 Late-Stage Products (Phase-III)
  • Figure 18 Mid-Stage Products (Phase-II)
  • Figure 19 Early-Stage Products (Phase-I)
  • Figure 20 Preclinical and Discovery Stage Products
  • Figure 21 Inactive Products
  • Figure 22 Dormant Products
  • Figure 23 Discontinued Products
  • Figure 24 Unmet Needs
  • Figure 25 Market Drivers and Barriers